Literature DB >> 11273208

Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort.

P Kaleebu1, A Ross, D Morgan, D Yirrell, J Oram, A Rutebemberwa, F Lyagoba, L Hamilton, B Biryahwaho, J Whitworth.   

Abstract

OBJECTIVE: To investigate the role of HIV-1 envelope subtypes on disease progression in a rural cohort of Ugandan adults where two major HIV-1 subtypes (A and D) exist.
METHODS: Participants of a clinical cohort seen between December 1995 and December 1998 had blood collected for HIV-1 subtyping. These included prevalent cases (people already infected with HIV at the start of the study in 1990) and incident cases (those who seroconverted between 1990 and December 1998). HIV-1 subtyping was carried out by heteroduplex mobility assay and DNA sequencing in the V3 env region. Disease progression was measured by the rate of CD4 lymphocyte count decline, clinical progression for the incident cases as time from seroconversion to AIDS or death, to first CD4 lymphocyte count < 200 x 10(6)/l and to the World Health Organization clinical stage 3. All analyses were adjusted for age and sex.
RESULTS: One hundred and sixty-four individuals, including 47 prevalent and 117 incident cases, had V3 env subtype data of which 65 (40%) were subtyped as A and 99 as D. In the incident cases, 44 (38%) were subtyped as A and 73 as D. There was a suggestion that for most end-points A had a slower progression than D. The cumulative probability of remaining free from AIDS or death at 6 years post-seroconversion was 0.72 [95% confidence interval (CI), 0.50 to 0.85] for A and 0.58 (95% CI, 0.42 to 0.71) for D, and the adjusted hazard ratio of subtype D compared to A was estimated to be 1.39 (95% CI, 0.66 to 2.94; P = 0.39). The estimated difference in rates of decline in square root CD4 lymphocyte counts was -0.41 per year (95% CI, -0.98 to 0.15; P = 0.15).
CONCLUSION: This study suggests that although subtype A may have a slower progression than D, HIV-1 envelope subtype is not a major factor in determining the progression of HIV-1 disease in a rural population in Uganda.

Entities:  

Mesh:

Year:  2001        PMID: 11273208     DOI: 10.1097/00002030-200102160-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

1.  A Semi-stationary Copula Model Approach for Bivariate Survival Data with Interval Sampling.

Authors:  Hong Zhu; Mei-Cheng Wang
Journal:  Int J Biostat       Date:  2015-05       Impact factor: 0.968

2.  Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS.

Authors:  Thangavel Samikkannu; Marisela Agudelo; Nimisha Gandhi; Pichili V B Reddy; Zainulabedin M Saiyed; Donald Nwankwo; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

3.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

4.  Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.

Authors:  Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  Virology       Date:  2013-12-12       Impact factor: 3.616

5.  Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes.

Authors:  Grant R Campbell; Jennifer D Watkins; Kumud K Singh; Erwann P Loret; Stephen A Spector
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins.

Authors:  Justine K Wong; Grant R Campbell; Stephen A Spector
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

7.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Infection with different hiv subtypes is associated with CD4 activation-associated dysfunction and apoptosis.

Authors:  Stephanie Bousheri; Candace Burke; Isaac Ssewanyana; Richard Harrigan; Jeffrey Martin; Peter Hunt; David R Bangsberg; Huyen Cao
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

9.  The human immunodeficiency virus type 1 promoter contains a CATA box instead of a TATA box for optimal transcription and replication.

Authors:  Tim van Opijnen; Joost Kamoschinski; Rienk E Jeeninga; Ben Berkhout
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.

Authors:  Bertran Auvert; Sylvia Males; Adrian Puren; Dirk Taljaard; Michel Caraël; Brian Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.